Provectus Provides Update on GI Tumor Program for Investigational Cancer Drug PV-10
08 juil. 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
Metastatic neuroendocrine tumors: Monotherapy data presentations planned. Phase 2 combination therapy trial designs with different classes of checkpoint inhibitor drugs being developed.Metastatic...
Provectus Provides Update on Metastatic Uveal Melanoma Clinical Development Program for Investigational Drug PV-10
21 mars 2019 08h00 HE
|
Provectus Biopharmaceuticals Inc.
KNOXVILLE, TN, March 21, 2019 (GLOBE NEWSWIRE) -- Provectus (OTCQB: PVCT) today provided updates on the Company's metastatic uveal melanoma drug development program for its lead investigational...
Esperion Announces Initiation of Three Pivotal Phase 3 Studies for Bempedoic Acid
08 janv. 2017 16h00 HE
|
Esperion Therapeutics, Inc.
Global Phase 3 Program Top-Line Results Expected Mid-2018 ANN ARBOR, Mich., Jan. 08, 2017 (GLOBE NEWSWIRE) -- Esperion Therapeutics, Inc. (NASDAQ:ESPR), the lipid management company focused on...